Affectis Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
Affectis Pharmaceuticals General Information
Description
Developer of drugs for the treatment of psychiatric and inflammatory disorders. The company discovers and develops drugs based on findings in the fields of depression, schizophrenia and inflammation.
Contact Information
Website
www.affectis.comCorporate Office
- Otto-Hahn-Straße 15
- 44227 Dortmund
- Germany
Corporate Office
- Otto-Hahn-Straße 15
- 44227 Dortmund
- Germany
Affectis Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 07-Jan-2014 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 22-Mar-2010 | Completed | Generating Revenue | |||
| 6. Grant | 08-Jul-2009 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 24-Oct-2006 | Completed | Startup | |||
| 4. Grant | 18-Oct-2005 | Completed | Startup | |||
| 3. Early Stage VC (Series B) | 13-Apr-2005 | Completed | Startup | |||
| 2. Grant | 31-Jan-2005 | $982K | $4.65M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 10-Nov-2003 | $4.65M | $4.65M | Completed | Startup |
Affectis Pharmaceuticals Patents
Affectis Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2012163456-A1 | Novel p2x7r antagonists and their use | Inactive | 27-May-2011 | ||
| WO-2012163792-A1 | Novel p2x7r antagonists and their use | Inactive | 27-May-2011 | ||
| WO-2012110190-A1 | Novel p2x7r antagonists and their use | Inactive | 17-Feb-2011 | ||
| AU-2011252351-A1 | Novel methods for the preparation of p2x7r antagonists | Inactive | 14-May-2010 | ||
| CA-2799115-A1 | Novel methods for the preparation of p2x7r antagonists | Inactive | 14-May-2010 | C07D209/40 |
Affectis Pharmaceuticals Signals
Affectis Pharmaceuticals Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adamant Biomedical Investment | Asset Manager | Minority | ||
| Aescap Life Sciences | Mutual Fund | Minority | ||
| Bayern Kapital | Venture Capital | Minority | ||
| EMBL Ventures | Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority |
Affectis Pharmaceuticals FAQs
-
When was Affectis Pharmaceuticals founded?
Affectis Pharmaceuticals was founded in 2002.
-
Where is Affectis Pharmaceuticals headquartered?
Affectis Pharmaceuticals is headquartered in Dortmund, Germany.
-
What is the size of Affectis Pharmaceuticals?
Affectis Pharmaceuticals has 2 total employees.
-
What industry is Affectis Pharmaceuticals in?
Affectis Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Affectis Pharmaceuticals a private or public company?
Affectis Pharmaceuticals is a Private company.
-
What is Affectis Pharmaceuticals’s current revenue?
The current revenue for Affectis Pharmaceuticals is .
-
How much funding has Affectis Pharmaceuticals raised over time?
Affectis Pharmaceuticals has raised $29.5M.
-
Who are Affectis Pharmaceuticals’s investors?
Adamant Biomedical Investment, Aescap Life Sciences, Bayern Kapital, EMBL Ventures, and EQT Life Sciences are 5 of 7 investors who have invested in Affectis Pharmaceuticals.
-
When was Affectis Pharmaceuticals acquired?
Affectis Pharmaceuticals was acquired on 07-Jan-2014.
-
Who acquired Affectis Pharmaceuticals?
Affectis Pharmaceuticals was acquired by LDC Beteiligungen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process